911845-41-5

Upstream product

• 38191-34-3 2-amino-5-bromophenol 
• 501-53-1 benzyl chloroformate 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 911845-37-9 (2Z)-4-(5-bromo-2-nitrophenoxy)but-2-en-1-ol 
• 911845-39-1 benzyl (Z)-(4-bromo-2-((4-hydroxybut-2-en-1-yl)oxy)phenyl)carbamate 
• 27684-84-0 5-bromo-2-nitrophenol 
• 911845-36-8 (2Z)-4-(5-bromo-2-nitrophenoxy)but-2-enyl propionate 

Downstream Products

• 1341208-56-7 N-{[(3S,3aS)-7-(3-nitrophenyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341208-57-8 N-{[(3S,3aS)-7-(4-cyanophenyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341208-59-0 N-{[(3S,3aS)-7-(3-aminophenyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341208-58-9 N-{[(3S,3aS)-7-(4-acetylphenyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341209-33-3 [(3R,3aS)-7-bromo-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin3-yl]methyl 3-nitrobenzene-1-sulfonate 
• 1341208-55-6 N-{[(3S,3aS)-1-oxo-7-phenyl-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 

Relevant academic research and scientific papers

Preparation method of a class of chiral epoxy compounds

The invention provides a synthetic method of a compound represented by a general formula I, an enantiomer of the compound, a diastereoisomer of the compound and a mixture of the enantiomer and the diastereoisomer. The method is safe, efficient, convenient to operate and suitable for commercial production. According to the invention, the use of explosive peroxides such as anhydrous tert-butyl hydroperoxide is avoided, the use of strong base sodium hydrogen or diisobutyl aluminum hydride is avoided, the operation is convenient and safe, the cost is low, the yield is high, and the ee value of theoptical purity is high.

Preparation method and application of oxazolidinone drug intermediate

The invention discloses a preparation method and application of an oxazolidinone drug intermediate. According to the preparation method provided by the invention, a synthesis procedure of a drug can be shortened, the product impurity is less, and the purity is high. The intermediate can be applied to synthesis of an oxazolidinone anticoagulant and an antibacterial agent, a cheap catalyst easy to get is adopted in synthesis of the anticoagulant intermediate, the use of a toxic phosphine ligand is avoided, and reaction can be carried out under a mild condition. A chemical formula is shown in thedescription.

Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis

A novel series of fluorine-containing benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles. Compound 21 exhibited not only outstanding in vitro a

Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents

A series of novel benzoxazinyl-oxazolidinones bearing nonaromatic heterocycle or aryl groups were designed and synthesized. Their in vitro and in vivo antibacterial activities were investigated. Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-positive pathogens. SAR trends were observed; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivatives with reduced activity. Various substituent group positions on the pyridyl ring were also evaluated. The resulting compounds displayed excellent activity against linezolid-resistant strains. Compound 45 exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid. In a MRSA systemic infection model, compound 45 displayed an ED 50 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid. This compound also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.

Stereocontrolled synthesis of tricyclic fused oxazolidinone as antibacterial agent

Tricyclic fused oxazolidinone 3a and 3b have been synthesized as antibacterial agents in 12 and 11 steps respectively. The key intermediates 10a and 10b have been developed via opening of epoxide 9a and 9b and cyclization by the resulting oxygen anion att